Physician-run telehealth — TN · FL · GA · OH · WA. One doctor reviews every case. No queue, no chatbot.
Summit
Apply now

Free educational tool

Which GLP-1 should I ask my provider about?

Six short questions. This quiz does not pick a medication or a dose for you. It gives you questions to bring to a provider, and below it you will find a plain side-by-side of what is FDA-approved today.

Nothing you choose is saved or sent anywhere. Your answers stay on this page and disappear when you close it. This is education, not medical advice. Only a licensed provider who knows your history can decide what, if anything, is appropriate for you.

I work in an emergency room. I have met people who started a medication they found online, with no one to explain how to take it, and ended up in real pain. They were not careless. They were missing information, and information is what good supervision gives you. I built this so you can walk into any provider’s office knowing what to ask. Dr. Paul Miranda

Question 1 of 6

What is FDA-approved today, side by side

This table is the same for everyone and is not ranked. Read it as background for your conversation, not as a way to choose. The label figures below come from separate trials with different people, lengths and ways of counting, so they cannot be lined up fairly. Only the two injections were compared head to head, in one open-label trial.

MedicationHow it is takenFDA statusLabeled uses (weight-related)Average weight change in a trialCommon stomach side effects in label trialsBoxed warning
Wegovy injection (semaglutide)Weekly injectionFDA-approved. Label read Nov 10, 2026.Lower the risk of heart attack, stroke or cardiovascular death in adults with established cardiovascular disease and obesity or overweight. Reduce excess body weight and maintain the reduction long term.13.7% at week 72 in the head-to-head trial with tirzepatide (SURMOUNT-5, open-label, maximum tolerated dose).Nausea 44% (placebo 16%), diarrhea 30% (16%), vomiting 24% (6%), constipation 24% (11%).Yes: risk of thyroid C-cell tumors.
Zepbound (tirzepatide)Weekly injectionFDA-approved Nov 2023. Label read Nov 10, 2026.Reduce excess body weight and maintain the reduction long term. Moderate to severe obstructive sleep apnea in adults with obesity.20.2% at week 72 in the same head-to-head trial (SURMOUNT-5).Highest-dose group: nausea 28% (placebo 8%), diarrhea 23% (8%), vomiting 13% (2%), constipation 11% (5%).Yes: risk of thyroid C-cell tumors.
Wegovy tablets (semaglutide)Daily pill, empty stomach with a small amount of water, then wait at least 30 minutes before eating, drinking or other pills.FDA-approved Dec 2025. Label read Nov 10, 2026.Same two uses as the Wegovy injection.13.6% at week 64 versus 2.2% with placebo (OASIS 4, published in the New England Journal of Medicine).The label says types and frequency were similar to the injection’s.Yes: risk of thyroid C-cell tumors.
Foundayo (orforglipron)Daily pill, with or without food.FDA-approved Apr 1, 2026. Label read Nov 10, 2026.Reduce excess body weight and maintain the reduction long term.11.1% at week 72 versus 2.1% with placebo, highest dose, adults without diabetes (label).Highest-dose group: nausea 35% (placebo 10%), diarrhea 25% (11%), vomiting 24% (4%), constipation 24% (9%).Yes: risk of thyroid C-cell tumors.
RetatrutideNot applicable. Investigational.Not FDA-approved. No approved use and no FDA label. Checked Nov 10, 2026.None.A phase 3 trial (TRIUMPH-1, funded by the manufacturer) was published in the New England Journal of Medicine on Nov 5, 2026. A trial report is not an approval, so no figure is shown here.The trial report lists stomach effects as the most common adverse events.Not applicable.
Compounded versions are a different category. A compounded medication is made for an individual patient and is not FDA-approved, and the FDA has not evaluated its safety, effectiveness or quality. If a provider offers a compounded preparation, ask exactly what it is, who makes it, and how it differs from the approved products above. Products sold online as retatrutide have not been evaluated by the FDA.

The approved labels say not to combine a GLP-1 medication with another semaglutide-containing product or another GLP-1 medication.

Want a physician to go through this with you?

At Summit, one physician reviews every case. Applying is not a prescription. A physician decides whether any medication is appropriate for you.

Apply for a physician review

Sources, checked Nov 10, 2026

Labels and approvals change. This page was prepared Nov 10, 2026 and may be out of date. Always check the current label and ask your provider.